ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $2.12 billion. The enterprise value is $2.72 billion.
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 984.97 million shares outstanding. The number of shares has increased by 25.58% in one year.
| Current Share Class | 984.97M |
| Shares Outstanding | 984.97M |
| Shares Change (YoY) | +25.58% |
| Shares Change (QoQ) | +6.57% |
| Owned by Insiders (%) | 30.02% |
| Owned by Institutions (%) | 15.16% |
| Float | 336.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.28 |
| Forward PS | 12.13 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.77
| Current Ratio | 5.77 |
| Quick Ratio | 5.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.89% |
| Return on Invested Capital (ROIC) | -53.22% |
| Return on Capital Employed (ROCE) | -56.46% |
| Revenue Per Employee | $121,404 |
| Profits Per Employee | -$512,671 |
| Employee Count | 680 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.84% in the last 52 weeks. The beta is -0.06, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -57.84% |
| 50-Day Moving Average | 2.39 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 46.35 |
| Average Volume (20 Days) | 8,877,106 |
Short Selling Information
The latest short interest is 73.75 million, so 7.49% of the outstanding shares have been sold short.
| Short Interest | 73.75M |
| Short Previous Month | 72.56M |
| Short % of Shares Out | 7.49% |
| Short % of Float | 21.93% |
| Short Ratio (days to cover) | 7.85 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $82.56 million and -$348.62 million in losses. Loss per share was -$0.42.
| Revenue | 82.56M |
| Gross Profit | 82.18M |
| Operating Income | -260.75M |
| Pretax Income | -348.69M |
| Net Income | -348.62M |
| EBITDA | -244.95M |
| EBIT | -260.75M |
| Loss Per Share | -$0.42 |
Full Income StatementBalance Sheet
The company has $257.81 million in cash and $861.29 million in debt, giving a net cash position of -$603.48 million or -$0.61 per share.
| Cash & Cash Equivalents | 257.81M |
| Total Debt | 861.29M |
| Net Cash | -603.48M |
| Net Cash Per Share | -$0.61 |
| Equity (Book Value) | -523.41M |
| Book Value Per Share | -0.53 |
| Working Capital | 272.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$319.70 million and capital expenditures -$5.05 million, giving a free cash flow of -$324.76 million.
| Operating Cash Flow | -319.70M |
| Capital Expenditures | -5.05M |
| Free Cash Flow | -324.76M |
| FCF Per Share | -$0.33 |
Full Cash Flow StatementMargins
| Gross Margin | 99.55% |
| Operating Margin | -315.84% |
| Pretax Margin | -422.38% |
| Profit Margin | n/a |
| EBITDA Margin | -296.71% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.58% |
| Shareholder Yield | -25.58% |
| Earnings Yield | -16.46% |
| FCF Yield | -15.34% |
Analyst Forecast
The average price target for ImmunityBio is $9.83, which is 357.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.83 |
| Price Target Difference | 357.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 163.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -9.31 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.31 |
| Piotroski F-Score | 4 |
